2014 IR News

RSS

IR News

11.25.2014 Santen Launches TAPCOM Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension

11.18.2014 Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Diabetic Macular Edema (DME), its Fourth Indication

11.12.2014 Santen and Singapore Eye Research Institute (SERI) Announce a Collaboration to Develop New Ophthalmic Therapeutics

10.31.2014 Santen Receives Financing from the Development Bank of Japan based on "DBJ Environmental Rating"

10.02.2014 Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck

09.25.2014 Increase of Capital for a Consolidated Subsidiary in Europe

09.22.2014 Intravitreal VEGF Inhibitor "EYLEA" Obtains Additional Indication of Myopic Choroidal Neovascularization (mCNV)

09.09.2014 Eyestrain Common Issue Caused by Contact Lenses!? Santen Launches Soft Santear Hitomi Stretch, an Eye Drop for Use with Soft Contact Lenses to Reduce Eyestrain by Relaxing Ciliary Muscle Stiffness Which Can Be a Cause of Eyestrain

09.01.2014 Notice on Details of the Rights to Subscribe for New Shares (Stock Options as Stock-Linked Remuneration)

08.15.2014 Santen Files for Manufacturing/Marketing Approval of its Glaucoma and Ocular Hypertension Therapeutic, COSOPT Mini Combination Ophthalmic Solution

08.05.2014 Santen to Grant Rights to Subscribe for New Shares as Stock Options as Stock-Linked Remuneration

08.05.2014 Medium-Term Management Plan FY2014-2017

07.29.2014 Changes in Significant Shareholders

07.02.2014 Santen Announces Closing of Asset Purchase Agreement with Respect to Acquisition of Ophthalmology Assets from Merck

05.13.2014 Santen Announces the Signing of Agreement between Merck for the Purchase of Assets in Ophthalmology

05.13.2014 Notice of the Nominations for the Member of the Board

05.13.2014 Santen Announces Financial Results for the Year ended March 31, 2014

04.07.2014 Santen Phase III Study Meets Primary Endpoint for The treatment of Non-Infectious Posterior Segment Uveitis (NI-PSU)

04.04.2014 Santen Partners with Akorn, Inc. subsidiary Oak Pharmaceuticals for Marketing of Tafluprost, the Treatment of Glaucoma and Ocular Hypertension in the U.S.

03.28.2014 The Osaka Study: An epidemiological survey showing that dry eye disease lowers work productivity, affects quality of life and correlates with metabolic syndrome

03.10.2014 Notice of the appointment of Corporate Officers

03.04.2014 Santen and TRACON Announce Agreement for the Development and Commercialization of TRC105 in Ophthalmology

02.20.2014 Changes in Significant Shareholders

02.04.2014 Santen Pharmaceutical Voluntarily Adopts International Financial Reporting Standards (IFRS)

02.04.2014 Revision of consolidated earnings forecasts for FY 2013